Myeloperoxidase antineutrophil cytoplasmic antibody(MPO-ANCA)associated vasculitis is an autoimmune disease usually with severe multiple dysfunction syndrome,especially prominent acute renal failure.A 65-year-old woma...Myeloperoxidase antineutrophil cytoplasmic antibody(MPO-ANCA)associated vasculitis is an autoimmune disease usually with severe multiple dysfunction syndrome,especially prominent acute renal failure.A 65-year-old woman was admitted with progressive dyspnoea for six months and fever,sputum with blood,pain of the lower extremities and intermittent claudication for two days,indicating multiple organ involvement(respiratory system,blood vessels).The renal involvement was relatively mild,presenting with microscopic haematuria.The chest computed tomography demonstrated multiple pulmonary embolisms.Ultrasound and computed tomography angiography for the lower extremity vessels showed venous and arterial thrombosis.Exclusion of other diseases that can cause multiple organ damage and thrombosis,the positive perinuclear ANCA and MPO-ANCA strongly support the diagnosis of MPO-ANAC-associated vasculitis.The patient’s physical condition has been greatly improved by treatment with corticosteroids and anticoagulation.展开更多
Renal fibrosis is the common pathological basis for the progressive development of chronic kidney disease(CKD)caused by various etiologies.It is characterized by the persistent deposition of extracellular matrix,leadi...Renal fibrosis is the common pathological basis for the progressive development of chronic kidney disease(CKD)caused by various etiologies.It is characterized by the persistent deposition of extracellular matrix,leading to renal tissue damage and impaired renal function,and ultimately progressing to kidney failure.Current clinical treatments for CKD mainly focus on managing the primary diseases,with no specific drugs targeting renal fibrosis.The pathogenesis of renal fibrosis is complex,and there are currently no drugs available to reverse it.A comprehensive overview of the pathogenesis of renal fibrosis,alongside a summary of current anti-fibrotic therapies,including some that are already used clinically to slow renal function progression,new drugs in clinical trials,and emerging targeted therapies,could provide new theoretical foundations and perspectives for the treatment of renal fibrosis.展开更多
文摘Myeloperoxidase antineutrophil cytoplasmic antibody(MPO-ANCA)associated vasculitis is an autoimmune disease usually with severe multiple dysfunction syndrome,especially prominent acute renal failure.A 65-year-old woman was admitted with progressive dyspnoea for six months and fever,sputum with blood,pain of the lower extremities and intermittent claudication for two days,indicating multiple organ involvement(respiratory system,blood vessels).The renal involvement was relatively mild,presenting with microscopic haematuria.The chest computed tomography demonstrated multiple pulmonary embolisms.Ultrasound and computed tomography angiography for the lower extremity vessels showed venous and arterial thrombosis.Exclusion of other diseases that can cause multiple organ damage and thrombosis,the positive perinuclear ANCA and MPO-ANCA strongly support the diagnosis of MPO-ANAC-associated vasculitis.The patient’s physical condition has been greatly improved by treatment with corticosteroids and anticoagulation.
基金supported by the National Natural Science Foundation(82173877 and 82073918)the Natural Science Foundation of Hunan Province(2024JJ5571)the Frontier Cross Project of Central South University(2023QYJC031),China.
文摘Renal fibrosis is the common pathological basis for the progressive development of chronic kidney disease(CKD)caused by various etiologies.It is characterized by the persistent deposition of extracellular matrix,leading to renal tissue damage and impaired renal function,and ultimately progressing to kidney failure.Current clinical treatments for CKD mainly focus on managing the primary diseases,with no specific drugs targeting renal fibrosis.The pathogenesis of renal fibrosis is complex,and there are currently no drugs available to reverse it.A comprehensive overview of the pathogenesis of renal fibrosis,alongside a summary of current anti-fibrotic therapies,including some that are already used clinically to slow renal function progression,new drugs in clinical trials,and emerging targeted therapies,could provide new theoretical foundations and perspectives for the treatment of renal fibrosis.
